- Clinical trials suggest first-ever safe and effective treatment to prevent multidrug-resistant TB in children and adults Medical Xpress
- Short oral regimens for pulmonary rifampicin-resistant tuberculosis (TB-PRACTECAL): an open-label, randomised, controlled, phase 2B-3, multi-arm, multicentre, non-inferiority trial The Lancet
- Indian drugmaker to supply key component of drug-resistant TB regimens University of Minnesota Twin Cities
- Landmark Clinical Trial Redefines Multidrug-Resistant Tuberculosis Treatment Options Doctors Without Borders
- View Full Coverage on Google News
Read original article here